Opioids and Opioid Addiction: Practical Management Approaches
|
|
- Tamsin Flynn
- 5 years ago
- Views:
Transcription
1 Opioids and Opioid Addiction: Practical Management Approaches Yngvild Olsen, MD, MPH Medical Director Institutes for Behavior Resources Inc/REACH Health Services
2 Conflict of Interest No financial or advisory relationships related to this activity
3 LEARNING OBJECTIVES Understand the key scientific and diagnostic elements of opioid use, opioid use disorder, and opioid addiction Describe the different options and role of medication-assisted treatment for opioid use disorder Understand the regulatory environment for use of opioids, treatment of opioid use disorders, and how this impacts patient management
4 Maryland statistics Reports/Quarterly%20report_2nd%20quarter%202016%20(1).pdf
5 Frank B. 28 yo male comes for a new patient visit on a Friday afternoon. You get a call from receptionist he s 15 minutes late so I told him we would need to reschedule but he s demanding to see you now and won t leave. Slightly disheveled, unshaven, wearing dirty jeans and a worn sweatshirt. Grumbles this is f.. up under his breath Demands a prescription for a controlled medication Your initial reaction?
6 Physician Attitudes and SUD Attitudinal surveys of medical students and residents demonstrate low regard for patients with SUDs Compared to hypertension, dyspepsia, pneumonia Lowest for opioid use disorder compared to alcohol use disorder Low levels of satisfaction caring for addicted patients among physicians in practice Some evidence that attitudes towards patients with SUD degrade over course of training and practice
7 Public Perception of Addiction Barry et al 2014: National randomized public opinion survey on mental illness and addiction 54% to 90% of respondents thought employment and housing could be denied to those with addiction, did not want to have co-workers with addiction, or want them to marry into family 15% to 59% thought the same for mental illness 43% opposed insurance parity for addiction vs 21% for mental illness Barry C et al. Psych Serv 2014
8 Brain Disease Model and Public Attitudes Australian social survey 2012*: Over 1,200 residents in Queensland Asked for level of agreement on a number of questions about: causality of addiction, disease models, role of coerced treatment, stigma, discrimination, and dangerousness Key Results: Over 50% believed alcohol and heroin addiction was a disease; only about 30% thought both were a brain disease 60% thought addiction was caused by personal character qualities Attitude is a little thing that makes a big difference ** *Meurk et al. BMC Psychiatry, **Ballon in Academic Psychiatry, 2008
9 Addiction Etiology Theories Moral failing or insufficient willpower VS Reward deficiency syndrome Deficiency of inhibitory control Disorder of choice Conditioned learning and habituation Self-medication of unrecognized underlying psychiatric disorder Disorder of bonding and connectedness To other humans To spiritual being
10 The Reward Pathway Source: NIDA.
11 Source: NIDA. The Human Brain
12 Pathophysiology of Addiction
13 THE BASIS FOR ADDICTION AS A DISEASE THE PERFECT STORM! Source: NIDA
14 Genetic Variants of the Human Mu Opioid Receptor: Single Nucleotide Polymorphisms in the Coding Region Including the Functional A118G (N40D) Variant HYPOTHESIS Gene variants: Alter physiology PHYSIOGENETICS Alter response to medications PHARMACOGENETICS Are associated with specific addictions Slide Source: Dr. Kreek Bond, LaForge Kreek, Yu, PNAS, 95:9608, 1998; Kreek, Yuferov and LaForge, 2000
15 Lifetime Prevalence and Odds Ratios of Mental Disorders by Substance Use Disorder: ECA Alcohol Drug Comorbid Disorder % O.R. % O.R. Any mental Schizophrenia Affective Anxiety Antisocial (Regier et al., JAMA 264: , 1990)
16 Trauma Impact Adverse Childhood Experiences Study: Over 8,000 adult men and women (mean age 57 and 55, respectively) Assessed history until age 18 of abuse/neglect, level of household dysfunction, health-related behaviors, and illicit drug use using standardized questionnaires Each participant assigned an ACE score based on number of experiences (analyzed as 0-5+) 67% had at least ACE; 42% had 2 or more Dube et al. Pediatrics, 2003
17 ACE Study Results: Initiation of Illicit Drug Use
18 ACE Study Results: Substance Use Disorder
19 Age of First Use Multiple studies demonstrate higher risk of adult onset substance use disorders with early onset of use before age 14 Higher vulnerability of adolescent brain -- significant developmental changes Changes in dopaminergic system Growth in prefrontal cortex Refinement of limbic neurocircuits Differential gene expression during adolescence compared to adulthood
20 Addictive Potential Determinants The faster a drug gets to the brain, the higher addictive potential The shorter acting a drug is, the higher addictive potential More potent drugs have higher addictive potential Takes less of drug to achieve effect
21 Addiction Definition A primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations.* A chronic, relapsing disease characterized by compulsive drug seeking and use despite harmful consequences as well as neurochemical and molecular changes in the brain.** A brain disease whose symptoms are overwhelming cravings and resultant behaviours. *American Society of Addiction Medicine **National Institute on Drug Abuse (NIDA)
22 Substance Use Disorder Diagnostic Criteria, DSM-5 More use than intended Excessive time spent in acquisition Unsuccessful efforts to cut down Activities given up because of use Craving for the substance Continued use despite consistent social or interpersonal problems Failure to fulfill major role obligations Tolerance* Use despite negative effects Withdrawal* Recurrent use in hazardous situations Severity measured by number of symptoms; 2-3 mild, 4-6 moderate, 7-11 severe * These do not apply if the medication is prescribed and no other diagnostic criteria are met
23 Physical Dependence Vs. Addiction Physical dependence is neither sufficient nor necessary to diagnose addiction. Dr. Howard Heit Physical dependence is a neuropharmacological phenomenon while addiction is both a neuropharmacological AND behavioral phenomenon. Physical dependence occurs with many different categories of medications and substances. Heit HA. Addiction, Physical Dependence, and Tolerance: Precise Definitions to Help Clinicians, Evaluate, and Treat the Patient with Chronic Pain. J Pain and Palliative Care Pharmacotherapy. March/April 2003;26:
24 Connect and Disconnect
25 Components of Comprehensive Addiction Treatment
26 No cure! Chronic Disease Goal is life long management Disease severity may change over time but risk of symptom recurrence is always present Behavior change is a key part of management Behavior change occurs in stages Effective treatment often combines medications and behavioral interventions
27 Mu Receptor Activation Full agonist mu receptor site Partial agonist methadone buprenorphine mu receptor site Antagonist naltrexone mu receptor site
28 Activity Levels Full Agonist (e.g. methadone) % Mu Receptor Intrinsic Activity But due to its ceiling maximum opioid agonist effect is never achieved Partial Agonist (e.g. buprenorphine) Like full agonists, partial agonist drugs produce increasing mu opioid receptor specific activity at lower doses no drug low dose DRUG DOSE high dose
29 Opioid Agonist Response vs. Heroin Response
30 Benefits Of Treatment Reduces risk of HIV infection Reduces risk of infection with hepatitis C and B Increases rates of employment among patients as a group Decreases crime Increases length of life
31 Treatment Effectiveness For Opioid Use Disorder Reduces drug use by 40-70% Addiction treatment is as successful as treatment of diabetes, asthma, and hypertension Strongest predictor of recovery is retention in treatment
32 Treatment Outcomes For Tapering off Medication In methadone studies, 50-80% relapse within one year after taper 91% of patients receiving buprenorphine for 4 months had relapsed to prescription opioids within 2 months of taper* Opioid overdose fatality rates are 3 to 20 times higher in the month after tapering off than during treatment *Weiss R. et al. NIDA CTN Prescription Opioid Treatment Study.
33 Reduced Mortality
34 2.5 Opioid Overdose Mortality Rates Before, During, and After Treatment with Methadone (per 100 person-years) Total Male Female Pre-Tx During Tx Post-Tx Clausen et al, Drug and Alc Depend 2008
35 Side Effects of Methadone and Buprenorphine Respiratory depression Sedation Constipation Decreased libido and sexual dysfunction Headache (primarily buprenorphine) Sweating (primarily methadone) Loss of appetite and dry mouth Nausea, vomiting Heart arrhythmias (high doses of methadone) Medication interactions Potential for misuse
36 Methadone/Buprenorphine and Other Substances Increased risk of acute opioid intoxication if mixed with alcohol Benzodiazepines potentiate sedative effects of opioids Overdoses have occurred in patients on buprenorphine and benzodiazepines Treatment may be needed for other substance use disorders but methadone or buprenorphine should be continued with appropriate dose adjustment to minimize sedation while balancing risk of illicit opioid relapse
37 Side effects of Naltrexone Nausea Fatigue Decreased appetite Insomnia Mild elevations in LFTs common, primarily with hep C Injection site reactions Precipitated withdrawal in opioid-tolerant individuals No long term studies past 12 months Significant drop out rates
38 Naltrexone and Other Substances Differences in individual metabolism of naltrexone noted Extremely high doses of heroin or fentanyl may override opioid blockade Approved for alcohol use DO Treatment still needed for other substances
39 Advancing Access to Addiction Medications National Guideline Conclusions The three pharmacotherapies have all shown clear clinical evidence of effectiveness in reducing opioid use and opioid use-related symptoms of withdrawal and craving as well as risk of infectious diseases and crime when used as part of a comprehensive treatment approach and in appropriate doses. The effectiveness of these medications is true only when used in continuing care, maintenance regimens; there remains almost no evidence of enduring benefits from any of these medications when used only in detoxification regimens. These medications have very different pharmacological properties and clinical roles. It is not presently known which of these medications is best for which type of patient or under which circumstance this should be the focus of additional research; particularly explorations of pharmacogenetic subtypes.
40 Indications for Medications All patients with opioid use disorder should be offered medication as a component of treatment The choice of medication is a medical decision between a physician and a patient Weighing complete history, physical examination, and relevant laboratory testing Factors to consider Methadone heavily structured and regulated Buprenorphine is expensive but less structured Naltrexone contra-indicated if prescription opioids are part of chronic pain treatment
41 HOW LONG IS LONG ENOUGH? Dennis M, et al, Eval Rev, 2007
42 Medications and Recovery SAMHSA recovery definition A process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential DSM 5 remission definitions 1. In early remission: After full criteria for opioid use disorder were previously met, none of the criteria for opioid use disorder have been met for at least 3 months but for less than 12 months. 2. In sustained remission: After full criteria for opioid use disorder were previously met, none of the criteria for opioid use disorder have been met at any time during a period of 12 months or longer. 3. On maintenance therapy: This additional specifier is used if the individual is taking a prescribed agonist medication such as methadone or buprenorphine and none of the criteria for opioid use disorder have been met for that class of medication (except tolerance to, or withdrawal from, the agonist). This category also applies to those individuals being maintained on a partial agonist, an agonist/antagonist, or a full antagonist such as oral naltrexone or depot naltrexone.
43 JAMA. 1913;60(6):
44 MANY PATHS TO RECOVERY!
45 Resources Advancing Access to Addiction Medications ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use practiceguideline.pdf?sfvrsn=18 Maryland Behavioral Health Administration Provider Clinical Support System Medication Assisted Treatment pcssmat.org
46 Questions? x119
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationMedical and Biological Basis of Addiction: Gaining a Better Understanding of Addictive Illness
Medical and Biological Basis of Addiction: Gaining a Better Understanding of Addictive Illness YNGVILD OLSEN, MD, MPH MEDICAL DIRECTOR INSTITUTES FOR BEHAVIOR RESOURCES, INC. NOVEMBER 7, 2015 MARYLAND
More informationMark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC
Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationOpioid Use Issues: All the Players
Opioid Use Issues: All the Players Objectives After review, the participant will be able to: 1) Identify criteria for opioid use disorders Andrew J. McLean, MD, MPH Medical Director, ND Department of Human
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More information4/5/2018 MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS OBJECTIVES DEFINITION OF ADDICTION APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H.
MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H. MEDICAL DIRECTOR, UNITYPOINT HEALTH MERITER/ NEWSTART ADJUNCT PROFESSOR, UNIVERSITY OF WISCONSIN MADISON
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationSubstance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationBuprenorphine and MAT 101
Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationOpioid Use Disorder Treatment: Buprenorphine Treatment Basics
Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationOpioid Overdose Epidemic A Crises and Opportunity
Opioid Overdose Epidemic A Crises and Opportunity Samuel M. Silverman MD, FAPA, DFASAM Assistant Clinical Professor, UConn Medical School Director, Medical Education Rushford, A Hartford HealthCare Partner
More informationMEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER JOHN E LOPES Jr., DHSC, PA-C Associate Professor, Physician Assistant Program Central Michigan University and Project Director Medication-assisted
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationOverview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationOpioid Analgesics: Responsible Prescribing in the Midst of an Epidemic
Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today
More informationSubstance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %
Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationUnderstanding Addiction Implications for Practice
Understanding Addiction Implications for Brad Lander PhD, LICDC-CS Clinical Director / Psychologist Talbot Hall - Addiction Medicine at The Ohio State University Wexner Medical Center 3 Reward System The
More informationIt s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs
It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs Ken Saffier, MD Maureen Strohm, MD May 7, 2017 Disclosures Ken Saffier, MD, has nothing
More information2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society
Pregnant Women Who Use Drugs: Stigma, Science and Society Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationAddiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017
Addiction Overview Causes Consequences Treatments Methadone/Buprenorphine 101 April 1, 2017 Diane A. Rothon MD Why? would you listen to this presentation Review the definition and neurobiology of addiction
More informationTreating Opioid Addiction
Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationSUBSTANCE USE DISORDER IN ADOLESCENT POPULATION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION ANNABELLE SIMPSON, MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationMental Health and Behavioral Health
Mental Health and Behavioral Health mpfc (AC) Insula Thal DS GP VS VS VTA VTA Hippo OFC Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Advancing Addiction Science Behavioral
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationDSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW
DSM-5 AND ASAM CRITERIA Presented by Jaime Goffin, LCSW MODULE 1: GOALS & OBJECTIVES What is your experience with using ASAM and DSM 5 criteria? What are your learning expectations for today? GOAL FOR
More informationDisclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond
Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to
More informationYouth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016
Youth, Opioid Use and Treatment Options CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016 Disclosures No propriety involvement in pharmaceutical companies Assessor, CPSO Methadone
More informationThe Opiate Crisis 4/6/18. April 9, Words are important. If you want to care for something, you call it a flower.
The Opiate Crisis Presented by Dr. Anahi Ortiz Franklin County Coroner April 9, 2018 Words are important. If you want to care for something, you call it a flower. If you want to kill something, you call
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationUnderstanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO
Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,
More informationSubstance Use and Mental Health Disorders: Challenges for Primary Care
Substance Use and Mental Health Disorders: Challenges for Primary Care Ted Parran MD FACP Carter and Isabel Wang Professor of Medical Education CWRU School of Medicine tvp@cwru.edu Euphoria Producing Drugs
More informationsubstance use and mental disorders: one, the other, or both?
substance use and mental disorders: one, the other, or both? Stephen Strobbe, PhD, RN, PMHCNS-BC, CARN-AP Dawn Farm Education Series St. Joe s Education Center, Ypsilanti, MI Tuesday, January 27, 2015
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationTreating Addiction as a Chronic Disease
Treating Addiction as a Chronic Disease Sarah E. Wakeman, MD, FASAM Medical Director, MGH Substance Use Disorder Initiative Assistant Professor of Medicine, Harvard Medical School Disclosures Neither I
More informationChapter 7. Screening and Assessment
Chapter 7 Screening and Assessment Screening And Assessment Starting the dialogue and begin relationship Each are sizing each other up Information gathering Listening to their story Asking the questions
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationLong term treatment for opioid dependence Antagonist therapy
Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse
More informationRestoration of Parenting Ability Through Treatment for Substance Use Disorders
Restoration of Parenting Ability Through Treatment for Substance Use Disorders DEBRA M. BARNETT, MD Board Certified in General Psychiatry, Addiction Psychiatry, Geriatric Psychiatry, and Forensic Psychiatry
More informationInfectious Disease and the Opioid Epidemic: Correctional Health
Infectious Disease and the Opioid Epidemic: Correctional Health Josiah Jody Rich, MD, MPH Professor of Medicine and Epidemiology, Brown University Director of the Center for Prisoner Health and Human Rights,
More informationSubstance Use Disorder Part One: The Basics of Recovery
Substance Use Disorder Part One: The Basics of Recovery Paula Heller Garland, MS, LCDC University of North Texas Department of Disability & Addiction Rehabilitation Workshop Overview How do you know that
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationThe Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options
The Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options Michelle R. Lofwall, MD UK Dept of Psychiatry November 4, 2008 Outline for Today s Talk Past & current state of affairs
More informationCouncil on Chemical Abuse Annual Conference November 2, The Science of Addiction: Rewiring the Brain
Council on Chemical Abuse Annual Conference November 2, 2017 The Science of Addiction: Rewiring the Brain David Reyher, MSW, CAADC Behavioral Health Program Director Alvernia University Defining Addiction
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More information5/30/ New England Summer School Lindy S. Keller, M.S., MLADC - NH Bureau of Drug & Alcohol Services. Objectives
2018 New England Summer School Lindy S. Keller, M.S., MLADC - NH Bureau of Drug & Alcohol Services Objectives Describe the neurological basis of addiction Explain how addiction manifests in various aspects
More informationRates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US,
Rates of Opioid Overdose Deaths, Sales, and Treatment Admissions: US, 1999 21 8 Rates of Prescription Painkiller Sales, Deaths, and Substance Abuse Treatment Admissions (1999 21) 7 Rate 6 5 4 3 Sales per
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationPain, Suffering, Over-Prescribing and Addiction What Have We Done, What Can We Do?
Pain, Suffering, Over-Prescribing and Addiction What Have We Done, What Can We Do? January 12, 2016 Trip Gardner, MD Chief Psychiatric Officer PCHC Noah Nesin, MD VP for Medical Affairs PCHC How Did We
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationPrimer on Opioid Use Disorders A Brain Disease
Primer on Opioid Use Disorders A Brain Disease Of people entering treatment for heroin addiction who began abusing opioids in the 1960s, more than 80% started with heroin. Of those who began abusing opioids
More informationMedicated Assisted Treatment
Medicated Assisted Treatment Enhancing the Potential for Recovery Part I Diana Padilla Program Manager NeC-ATTC 2 Diana Padilla, RCR, CASAC-T padilla@ndri.org Diana Padilla is a program manager at NDRI-USA,
More informationNational Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says
National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More information